Moving Forward in the Treatment of Crohn's Disease
Apply for CME Credit Online
Purpose
This program is intended to educate healthcare providers, through expert examination and discussion, about new and promising treatment options for Crohn’s Disease. Discussants are Dr. Russell Cohen, Dr. Scott Plevy, and Dr. Edward Loftus
Program Overview
Many classes of pharmacological agents are currently being utilized by clinician's to help manage Crohn's disease. However, typical medical therapy, including agents such as aminosalicylates, corticosteroids and immunomodulators, do not completely control the disease in many patients and are often associated with various side effects. Thus, newer approaches to therapy represent a significant need for healthcare providers involved in the diagnosis and management of Crohn's disease.
Audience
Clinical gastroenterologists in academia and community practice, gastroenterology trainees, nurse practitioners, physician assistants, as well as other GI healthcare providers.
Learning Objectives
This Conversations program, focused on the effective management of patients with Crohn’s disease, will enable participants to:
- Identify the limitations of current agents commonly used to treat and manage Crohn's disease
- List the new and investigational therapies for the medical management of Crohn's disease
- Understand the targets for therapeutic intervention of the new and investigational therapies
Accreditation Statement
The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
The AGA Institute designates this educational activity for a maximum of
0.5 AMA PRA Category 1 Credit(s)TM.
Physicians should only claim credit commensurate with the extent of their participation in the activity.
Faculty
Russell Cohen, MD (Program Moderator) Associate Professor of Medicine
University of Chicago School of Medicine
Edward V. Loftus, Jr, MD
Associate Professor of Medicine
Mayo Medical School
Scott Eric Plevy, MD
Associate Professor of Medicine
University of North Carolina School of Medicine
Chapel Hill, NC
Faculty Disclosure Information
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
Russell Cohen, MD
Grant/Research Support: Centecor
Speakers' Bureau: Abbott, Astra-Zeneca, Axcan-Scandipharm, Proctor and Gamble, Prometheus, Salix, Schering-Plough, Shire, Tanabe, UCB
Consultant: Abbott, Axcan-Scandipharm, Centecor, Elan, Isis, NPS, Protein-Design Labs, UCB
Additional Disclosure: Family member who works for Centecor and owns stock in Johnson and Johnson
Edward V. Loftus, Jr, MD
Grant/Research Support: Abbott, Schering-Plough
Consultant: Abbott, UCB, Elan, Prometheus, Shire
Scott Eric Plevy, MD
Grant/Research: Callisto Pharmaceuticals, Centocor, Inc., Genentech, Inc., Protein Design Labs, Senesco Technologies, Inc.
Consultant: Abbott Immunology, Berlex, Callisto Pharmaceuticals, Celgene Corporation, Centocor, Inc., Dynogen, Inc., Elan, Genentech, Inc., Johnson & Johnson, Otsuka Pharmaceuticals, Prometheus Labs, Protein Design Labs, Senesco Technologies, Inc., Shire, Synta Pharmaceuticals, Tanabe Pharmaceuticals, UCB, Takeda Pharmaceuticals
Other: Prometheus Labs
Suggested Minimum Software Requirements
Windows Me / XP / 2000.
800 MHz P3 processor.
256 MB RAM.
Microsoft Internet Explorer (6.0 or higher).
16-bit sound card and Windows Media Player (9.0 or greater).
Video Card capable of 16-bit color.
Adobe Reader 6.0 or greater.
Release Date
May 2007
Expiration Date
May 2009
Fee
Free-of-charge
Sponsorship and Support
Sponsored by the AGA Institute. This program is supported through an educational grant from Elan Pharmaceuticals, Inc., and Biogen Idec.